Regeneron Stock is Weak as Profits are Strong
April 11, 2021
Regeneron (REGN) is growing profits rapidly, but the stock is down from $60 to $475 since last Summer. Why?
Research Reports
Regeneron is a Real Deal With a P/E of Only 14
December 11, 2020
Regeneron (REGN) stock has ben pushed aside while investors pour money into growth stocks. Now REGN looks like a deal.
Regeneron Has a Lot to Offer, Perhaps Even a COVID Cocktail
October 22, 2020
Biotech drug company Regeneron (REGN) has a lot to offer investors, including eye, cancer and eye medications.
Regeneron Needs a Blockbuster to Regain Momentum
April 3, 2018
Regeneron (REGN) stock has been on a steady slide down since last Summer, as investors grow show lack of faith in a future blockbuster.
Regeneron’s Acting Bad, But Looking Good
February 6, 2018
Regeneron (REGN) stock has been acting bad lately, but the Biotech’s got a P/E around 20, making it a good bet for long-term patient investors. At least I think so.
Regeneron Estimates Rise for the 1st Time Since 2015
October 25, 2017
Analysts had been taking down 2017 profit estimates for Regeneron (REGN) since 2015. Wow! But that all changed last qtr when REGN beat the street and numbers rose.
Is Regeneron Worth the High Price it Sells for?
July 24, 2017
Is Regeneron (REGN) worth the five hundred or so dollars a share the stock is selling for? Or is it up because of renewed appreciation for Biotechs.
Regeneron and Its Big Three Drugs
March 28, 2017
Regeneron (REGN) has 16 drugs in development, but the company really has three big drugs that affect can and will profits now and in the future.
Court Rules to Take Regeneron’s Praluent off the Market
January 7, 2017
Yesterday a US court issued a permanent injunction prohibiting Regeneron (REGN) from selling Praluent in the US. Profit estimates will be coming down.
Praluent Was Supposed to Be Regeneron’s Next Blockbuster
October 10, 2016
Praluent was supposed to be Regeneron’s (REGN) next blockbuster drug. But disappointing sales are causing analysts to reel in estimates.
Regeneron’s Chart Looks Sick
July 7, 2016
Regeneron’s (REGN) stock chart looks sick, and may foretell bad news ahead in regards to its Praluent battle with Amgen.
Lots of Pressure on Shares of Regeneron
March 17, 2016
Investors in Regeneron (REGN) have a lot to deal with nowadays, including a patent issue, reduction in profit estimates, and negative political backdrop.
Regeneron is on the Fast Track
January 2, 2016
Regeneron (REGN) is on a fast-track of profit and stock growth. I feel that trend will continue well into the future.
Buying This Biotech On Weakness
September 28, 2015
Today Regeneron (REGN) has fallen to $450 and I will use this opportunity to buy the stock.
Buy Regeneron If It Gets Down To…
September 2, 2015
Regeneron (REGN) has been a market darling, and with the stock market correction, REGN is down too. Here’s where I plan on buyign in.
Regeneron at $400
October 28, 2014
Regeneron (REGN) pushed thru $400 last week on good Eylea news, even though earnings estimates didn’t rise.
Before the Pop
February 12, 2014
Shares of Regeneron (REGN) are running so fast I can’t keep up. Here’s what REGN looked like last week,